Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.02.009
Abstract: INTRODUCTION There is unmet need to explore the predictive biomarkers of PD-1/PD-L1 inhibitors in patients with non-small-cell lung cancer (NSCLC). Here, we aimed to investigate the predictive and prognostic value of blood neutrophil-to-lymphocyte ratio (NLR)… read more here.
Keywords: treated inhibitors; blood; value; lung cancer ... See more keywords
Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2023.2208351
Abstract: ABSTRACT Background A meta-analysis method was used to investigate the prognostic value of CD8+ tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors. Methods A database search of PubMed, Embase,… read more here.
Keywords: meta analysis; patients treated; treated inhibitors; cd8 tils ... See more keywords
Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB
Sign Up to like & getrecommendations! Published in 2022 at "Disease Markers"
DOI: 10.1155/2022/7137357
Abstract: Background To assess the prognostic value of pretreatment serum biomarkers in stage IV non-small-cell lung cancer (NSCLC) patients treated with PD-1 (programmed cell death protein 1) inhibitors and their value as a predictor of benefit.… read more here.
Keywords: lmr pab; serum biomarkers; treated inhibitors; nlr dnlr ... See more keywords
Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2017 at "Immunotherapy"
DOI: 10.2217/imt-2016-0147
Abstract: AIM We conducted this meta-analysis to investigate the overall incidence and risk of endocrine complications in cancer patients treated with PD-1 inhibitors. METHODS Pubmed, Embase and oncology conference proceedings were searched for relevant studies. RESULTS… read more here.
Keywords: treated inhibitors; risk; patients treated; cancer patients ... See more keywords
A composite indicator of derived neutrophil–lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.951985
Abstract: Background There are currently no established biomarkers that can predict whether advanced pancreatic carcinoma (PC) patients would benefit from immune checkpoint inhibitors (ICIs). Our study investigated whether the pretreatment composite biomarker of derived neutrophil–lymphocyte ratio… read more here.
Keywords: dnlr ldh; group; risk; treated inhibitors ... See more keywords